Impaired Hepatic Function
8
0
0
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
25.0%
2 terminated out of 8 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Study of ALXN2050 in Participants With Hepatic Impairment
Evaluating Patients With Impaired Hepatic Function
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
Effect of Hepatic Impairment on LDE225..
Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011